RxDoctor Payments Data

Monica Ortiz-Rivera, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1063962058

Payments from drug & device makers

What this record shows

This record is dominated by grants: $140,625 of the $147,655 with a category attached, or 95.2%. Eli Lilly Export S.A. Puerto Rico Branch accounts for 63.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $94,456 and has fallen 98.7% since, to $1,272 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$147,655in general payments, 2019–2025

Across 196 payments — averaging $753.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$94K
  • Eli Lilly$47K
  • Medtronic$959
  • Boehringer Ingelheim$825
  • Dexcom, Inc.$687
  • Novo Nordisk$665
  • plus $4K from 18 others

What the payments were for

  • Grants$140,62595%
  • Travel & lodging$7851%
  • Food & beverage$6,1514%
  • Education$950%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,655 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$16,248
Medicare patients
54
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$102,715
MounjaroTirzepatide71$76,165
JardianceEmpagliflozin71$66,148
Jentadueto XrLinagliptin/Metformin Hcl99$56,537
Synjardy XrEmpagliflozin/Metformin Hcl81$53,227
Janumet XrSitagliptin Phos/Metformin Hcl67$52,180
Trijardy XrEmpaglifloz/Linaglip/Metformin73$51,663
GlyxambiEmpagliflozin/Linagliptin47$34,862
TradjentaLinagliptin54$34,275
SynthroidLevothyroxine Sodium303$23,493
FarxigaDapagliflozin Propanediol25$23,296
TrulicityDulaglutide21$20,752
Xigduo XrDapaglifloz Propaned/Metformin16$18,067
LantusInsulin Glargine,hum.Rec.Anlog103$11,079
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto Xr, Synjardy Xr, Trijardy Xr, Glyxambi$825$296,713425 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$463$105,943187 claims
Novo NordiskOzempic$665$102,71599 claims
MerckJanumet Xr$72$52,18067 claims
AbbVieSynthroid$36$23,493303 claims
AstraZenecaFarxiga$306$23,29625 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$532$21,872115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →